BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 21503588)

  • 21. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties.
    Prodosmo A; Giglio S; Moretti S; Mancini F; Barbi F; Avenia N; Di Conza G; Schünemann HJ; Pistola L; Ludovini V; Sacchi A; Pontecorvi A; Puxeddu E; Moretti F
    J Mol Med (Berl); 2008 May; 86(5):585-96. PubMed ID: 18335186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status.
    Flørenes VA; Maelandsmo GM; Forus A; Andreassen A; Myklebost O; Fodstad O
    J Natl Cancer Inst; 1994 Sep; 86(17):1297-302. PubMed ID: 8064888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.
    Xiong S; Van Pelt CS; Elizondo-Fraire AC; Liu G; Lozano G
    Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3226-31. PubMed ID: 16492743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
    Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
    Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf
    Chapeau EA; Gembarska A; Durand EY; Mandon E; Estadieu C; Romanet V; Wiesmann M; Tiedt R; Lehar J; de Weck A; Rad R; Barys L; Jeay S; Ferretti S; Kauffmann A; Sutter E; Grevot A; Moulin P; Murakami M; Sellers WR; Hofmann F; Jensen MR
    Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3151-3156. PubMed ID: 28265066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
    Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
    Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.
    Parant J; Chavez-Reyes A; Little NA; Yan W; Reinke V; Jochemsen AG; Lozano G
    Nat Genet; 2001 Sep; 29(1):92-5. PubMed ID: 11528400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The MDM2 gene family.
    Mendoza M; Mandani G; Momand J
    Biomol Concepts; 2014 Mar; 5(1):9-19. PubMed ID: 25372739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer.
    Swetzig WM; Wang J; Das GM
    Oncotarget; 2016 Mar; 7(13):16049-69. PubMed ID: 26909605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development.
    Steinman HA; Hoover KM; Keeler ML; Sands AT; Jones SN
    Oncogene; 2005 Nov; 24(53):7935-40. PubMed ID: 16027727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between MDM2 and p53 alterations in colorectal cancer and their involvement and prognostic value in the Tunisian population.
    Chaar I; Amara S; Khiari M; Ounissi D; Dhraif M; Ben Hamida AE; Gharbi L; Mzabi S; Bouraoui S
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):228-36. PubMed ID: 22914606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dysfunction of p53 pathway in human colorectal cancer: analysis of p53 gene mutation and the expression of the p53-associated factors p14ARF, p33ING1, p21WAF1 and MDM2.
    Tachibana M; Kawamata H; Fujimori T; Omotehara F; Horiuchi H; Ohkura Y; Igarashi S; Kotake K; Kubota K
    Int J Oncol; 2004 Oct; 25(4):913-20. PubMed ID: 15375540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.
    Ohnstad HO; Castro R; Sun J; Heintz KM; Vassilev LT; Bjerkehagen B; Kresse SH; Meza-Zepeda LA; Myklebost O
    Cancer; 2013 Mar; 119(5):1013-22. PubMed ID: 23165797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.
    Habuchi T; Kinoshita H; Yamada H; Kakehi Y; Ogawa O; Wu WJ; Takahashi R; Sugiyama T; Yoshida O
    J Natl Cancer Inst; 1994 Sep; 86(17):1331-5. PubMed ID: 8064891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas.
    Grünewald I; Trautmann M; Busch A; Bauer L; Huss S; Schweinshaupt P; Vollbrecht C; Odenthal M; Quaas A; Büttner R; Meyer MF; Beutner D; Hüttenbrink KB; Wardelmann E; Stenner M; Hartmann W
    Oncotarget; 2016 Nov; 7(46):75261-75272. PubMed ID: 27662657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
    Pilotti S; Della Torre G; Lavarino C; Di Palma S; Sozzi G; Minoletti F; Rao S; Pasquini G; Azzarelli A; Rilke F; Pierotti MA
    J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p53 as a target for the treatment of cancer.
    Duffy MJ; Synnott NC; McGowan PM; Crown J; O'Connor D; Gallagher WM
    Cancer Treat Rev; 2014 Dec; 40(10):1153-60. PubMed ID: 25455730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis.
    Gansmo LB; Lie BA; Mæhlen MT; Vatten L; Romundstad P; Hveem K; Lønning PE; Knappskog S
    Gene; 2021 Aug; 793():145747. PubMed ID: 34077778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered patterns of MDM2 and TP53 expression in human bladder cancer.
    Lianes P; Orlow I; Zhang ZF; Oliva MR; Sarkis AS; Reuter VE; Cordon-Cardo C
    J Natl Cancer Inst; 1994 Sep; 86(17):1325-30. PubMed ID: 8064890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.